Related news
-
Immunotherapies, biosimilars to dominate next week of earnings
Published: 24/04/2018AbbVie, Bristol-Myers, Celgene, Roche, AstraZeneca and others will report first quarter earnings over the coming days. Read moreSource: www.biopharmadive.com -
-
As Spinraza sales fall, Biogen talks up adult SMA opportunity
Published: 24/04/2018While the big biotech remains optimistic, analysts and investors were skeptical about where growth will come from. Read moreSource: www.biopharmadive.com -
Lilly raises sales forecasts as diabetes drugs outperform
Published: 24/04/2018Strengthening uptake of Trulicity, coupled with higher-than-expected revenue from older insulin products, helped the pharma beat market estimates. Read moreSource: www.biopharmadive.com
-
Orexigen agrees to sale, but is open to more offers
Published: 24/04/2018Company leadership realized it's time to slim down and has accepted an acquisition offer. But there's still time for other buyers to submit a bid. Read moreSource: www.biopharmadive.com -
Prothena pulls Phase 3 drug, stock plummets
Published: 24/04/2018The Irish biotech scraped its amyloidosis candidate after a late-stage futility analysis returned disappointing results. Read moreSource: www.biopharmadive.com -
Lilly's baricitinib wins FDA panel nod, but still dogged by safety issues
Published: 24/04/2018Lilly entered the Food and Drug Administration committee meeting on Monday with a fuzzy outlook for its potentially billion-dollar arthritis drug. It left in much the same fashion. Read moreSource: www.biopharmadive.com
-
Pharma supply chains could use a tech reboot
Published: 23/04/2018While more prosaic than drug R&D, supply chains are increasingly important as the industry moves toward personalized medicine. Read moreSource: www.biopharmadive.com -
Mylan cuts workforce at West Virginia plant by 15%
Published: 23/04/2018The announcement leaves approximately 3,000 employees at the Morgantown location, a site that is primarily dedicated to production of oral drugs. Read moreSource: www.biopharmadive.com -
The Drug Supply Chain Security Act: A progress report
Published: 23/04/2018Five years in and one enforcement extension later, pharmaceutical companies still have a long way to go to fulfill the goal of true traceability. Read moreSource: www.biopharmadive.com
-
Top challenges facing drug supply chains
Published: 23/04/2018Issues like GMP compliance and cold-chain shipping are just two of the hurdles that must be overcome for medicines to travel from drugmakers to patients. Read moreSource: www.biopharmadive.com -
As India, China drug industries mature, FDA scrutiny an overhang
Published: 23/04/2018Rising numbers of warning letters have put production quality in focus, just as both countries turn further toward novel drug R&D. Read moreSource: www.biopharmadive.com -
CAR-T ups challenges in pharma supply chain
Published: 23/04/2018New technology made shipping the cell therapies viable. Now, stakeholders are pushing for more innovation to meet looming commercial demands. Read moreSource: www.biopharmadive.com
-
Brain Talk: Tackling a crisis while treating the patient
Published: 23/04/2018The human brain is a marvelous, complex organ. It controls so much of the body, and yet so little is known about it. But every day, new research opens doors to the brain’s inner workings, sheddi ... Read moreSource: www.biopharmadive.com -
Pfizer's Herceptin copy hits FDA roadblock
Published: 23/04/2018Regulators handed Pfizer a Complete Response Letter four months after approving Mylan's copycat version of the breast cancer drug. Read moreSource: www.biopharmadive.com -
Novartis bolsters case for siponimod with new data
Published: 23/04/2018The results support Novartis' filing of the drug, which the pharma hopes will secure FDA approval for secondary progressive MS. Read moreSource: www.biopharmadive.com
-
Merck antibiotic data positive in Phase 3
Published: 23/04/2018The promising data moves the pharma closer to a submission to the FDA. Read moreSource: www.biopharmadive.com -
Alnylam, Dicerna settle RNAi trade secrets lawsuit
Published: 21/04/2018Two makers of the gene-silencing technology settled a years-long lawsuit days ahead of a scheduled jury trial date. Read moreSource: www.biopharmadive.com -
GW wins panel backing for Epidiolex, looks to FDA decision
Published: 20/04/2018Following an advisory committee's unanimous recommendation for Epidiolex, GW Pharma awaits a June decision on approval by the regulator. Read moreSource: www.biopharmadive.com
-
Biogen, facing questions, turns again to Ionis in $1B research deal
Published: 20/04/2018Tapping the discovery expertise of Ionis, however, may not placate investors eager to see Biogen pad its pipeline with more aggressive dealmaking. Read moreSource: www.biopharmadive.com -
Prescribed Reading: Shire on the block; FDA flip-flops
Published: 20/04/2018There are potentially multiple suitors looking to take out Shire. Elsewhere, the FDA is making surprise reversals. Read moreSource: www.biopharmadive.com -
Out-of-pocket drug costs still murky, report underscores
Published: 20/04/2018A recent look at drug costs for patients from Iqvia suggests they have, on average, fallen. Whether that's partially because of discounts and rebates remains unclear. Read moreSource: www.biopharmadive.com
Related Hashtags
Most read
-
Avengers: Infinity War Drama, Male Actor Treats Interviewer Horribly
Source: ohnotheydidnt.livejournal.com -
Popular Sleep Cycle iPhone App Expands to Apple Watch With 'Snore Stopper' and Haptic Wake Up Features
Source: www.macrumors.com -
Battle royale hybrid 'Darwin Project' is now free to play
Source: www.engadget.com -
Local Chatbot Platforms Like Senseforth and Haptik Remain a Viable Option Thanks to Customisation
Source: gadgets.ndtv.com -
The Duchess of Cambridge is making fecundity fashionable again
Source: spectator.co.uk -
A Guide To Penn State’s Best Library Study Spots
Source: onwardstate.com -
'Abhay Deol dancing is the USP of our film'
Source: www.rediff.com -
Indie Pop Band Saint Motel Brings Energetic Act To Penn State
Source: onwardstate.com
FACEBOOK